Back | Next |
home / stock / avxl / avxl message board
Subject | By | Source | When |
---|---|---|---|
You are absolutely correct about the following: | georgejjl | investorshub | 07/17/2024 3:43:05 PM |
An indictment-induced CEO resignation will do that to | boi568 | investorshub | 07/17/2024 3:42:49 PM |
were is the landing? | KIPK | investorshub | 07/17/2024 3:34:03 PM |
ouch! that hurts, but true | sab63090 | investorshub | 07/17/2024 3:09:31 PM |
My question: | sab63090 | investorshub | 07/17/2024 3:06:14 PM |
looks more like a drop from a 25 | sab63090 | investorshub | 07/17/2024 3:00:55 PM |
Early in the day observation: | sab63090 | investorshub | 07/17/2024 2:58:00 PM |
Seems to me that both the CEO and | sab63090 | investorshub | 07/17/2024 2:44:25 PM |
As it happens a lead plaintiff was appointed | Investor2014 | investorshub | 07/17/2024 2:11:10 PM |
Eggzactly. | ignatiusrielly35 | investorshub | 07/17/2024 1:49:41 PM |
No idea why you would invest in SAVA | Hosai | investorshub | 07/17/2024 1:36:20 PM |
FDA staff is probably reviewing any correspondence it's | boi568 | investorshub | 07/17/2024 1:35:02 PM |
Ouch. Say what you want about Dr. | tredenwater2 | investorshub | 07/17/2024 1:19:01 PM |
How about a board with the CEOs uni | Investor2014 | investorshub | 07/17/2024 1:13:17 PM |
The 2021 parabolic rise to 100+ was ridiculous | Doc328 | investorshub | 07/17/2024 1:11:36 PM |
Take it however you can get it. | boi568 | investorshub | 07/17/2024 1:11:24 PM |
Im confident your comment is idiotic. | Investor2014 | investorshub | 07/17/2024 1:09:23 PM |
A cloud will hang over the company. | Doc328 | investorshub | 07/17/2024 1:05:56 PM |
Lol saw it is as struggles and stumbles, | frrol | investorshub | 07/17/2024 1:05:22 PM |
Their larger AD clinical program not withstanding, it | frrol | investorshub | 07/17/2024 1:03:44 PM |
News, Short Squeeze, Breakout and More Instantly...
Anavex Life Sciences Corp. Company Name:
AVXL Stock Symbol:
NASDAQ Market:
Anavex Life Sciences Corp. Website:
Oral, once daily blarcamesine significantly slowed clinical decline for early Alzheimer's disease patients with good comparative safety profile and no associated neuroimaging adverse events Clinical benefit of blarcamesine consistently observed for both 30 mg and 50 mg treatment groups ...
2024-07-18 02:34:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
NEW YORK, June 20, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative, neurodevelopmental and neuropsyc...